rheumatoid arthritis Archives - Page 10 of 219

Abstract Number: 1091 • ACR Convergence 2025
Safety Profile of ICIs in Patients with Rheumatoid Arthritis: Results from a Propensity Score-Matched Cohort Study
Betul Ibis¹, Furkan Bahar¹, Yu-Che Lee², Ko-Yun Chang³, Yu Chang⁴ and Cho-Han Chiang⁵, ¹Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, ²University at Buffalo, Buffalo, NY, ³National Jewish Health, Denver, CO, ⁴National Cheng Kung University Hospital, Tainan, Taiwan (Republic of China), ⁵Mount Auburn Hospital, Harvard Medical School, Cambridge
Background/Purpose: Immune-related adverse events (irAEs) are a significant concern for patients receiving immune checkpoint inhibitors (ICIs), particularly those with pre-existing rheumatoid arthritis (RA). Managing ICIs…
Abstract Number: 1016 • ACR Convergence 2025
Association between inflammatory biomarkers and predicted heart failure risk in rheumatoid arthritis
Ilana Usiskin¹, Lauren rusnak², Katherine Zhong³, Ying Qi⁴, Nicole Yang², Gregory McDermott⁵, Brittany Weber⁶ and Katherine Liao², ¹Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital, Boston, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Short Hills, NJ, ⁴Brigham and Women’s Hospital, Boston, ⁵Brigham and Women's Hospital, Brookline, MA, ⁶Brigham and Women's Hospital, DEDHAM, MA
Background/Purpose: Heart failure (HF) is a major cause of morbidity and mortality in rheumatoid arthritis (RA). Prior work has suggested that higher levels of inflammation…
Abstract Number: 0917 • ACR Convergence 2025
Synovial Tissue Neutrophils are Associated with Disease Activity and Early Remission in Rheumatoid Arthritis
Annabelle Small¹, Vincent Wong², Christopher Altmann¹, Helen Weedon³, Malcolm Smith⁴, Susanna Proudman⁵ and Mihir Wechalekar⁶, ¹Flinders University, Bedford Park, South Australia, Australia, ²College of Medicine and Public Health, Bedford Park, South Australia, Australia, ³Flinders University of South Australia, Bedford Park, South Australia, Australia, ⁴Flinders University, Adelaide, South Australia, Australia, ⁵Royal Adelaide Hospital and University of Adelaide, Medindie, South Australia, Australia, ⁶Flinders Medical Centre and Flinders University, Bedford Park, South Australia, Australia
Background/Purpose: Neutrophils drive local pathology of rheumatoid arthritis (RA) in the synovial tissue (ST) through local production inflammatory mediators, cytokines, and extracellular traps. However, despite…
Abstract Number: 0831 • ACR Convergence 2025
Altered expression of CD11c and HLA-DR on monocyte subsets in individuals at risk of rheumatoid and psoriatic arthritis
Klára Prajzlerová¹, Olga Kryštůfková², Hana Hulejová¹, Nora Růžičková², Petra Hánová¹, Jiri Vencovsky³, Ladislav Šenolt², Jiří Štolfa² and Mária Filková², ¹Institute of Rheumatology, Prague, Czech Republic, ²Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ³Institute of Rheumatology, Praha ⁸, Czech Republic
Background/Purpose: Preclinical phases of rheumatoid arthritis (RA), including therapeutic interventions, have been extensively studied. There is a growing focus on individuals at risk for psoriatic…
Abstract Number: 0504 • ACR Convergence 2025
Spatial profiling of gene signatures in synovial tissue informs treatment strategy for Rheumatoid Arthritis
Vincent Wong¹, Katie Lowe², Annabelle Small³, Christopher Altmann³, Susanna Proudman⁴, Malcolm Smith², Wittaya Suwakulsiri⁵, Ranjeny Thomas⁵, Chung Hoow Kok⁶ and Mihir Wechalekar⁷, ¹College of Medicine and Public Health, Bedford Park, South Australia, Australia, ²Flinders University, Adelaide, South Australia, Australia, ³Flinders University, Bedford Park, South Australia, Australia, ⁴The University of Adelaide, Adelaide, Victoria, Australia, ⁵Frazer Institute, University of Queensland, Brisbane, Queensland, Australia, ⁶Centre for Cancer Biology, and Clinical Health Sciences, University of South Australia, Adelaide, South Australia, Australia, ⁷Flinders Medical Centre and Flinders University, Bedford Park, South Australia, Australia
Background/Purpose: Rheumatoid arthritis (RA) shows heterogeneous therapeutic responses that may reflect diversity within synovial tissue (ST). We aimed to identify gene signatures that predict Adalimumab…
Abstract Number: 0487 • ACR Convergence 2025
Efficacy of sarilumab in patients with rheumatoid arthritis of different disease activity at treatment initiation: a post-hoc analysis of a Phase 3 trial of sarilumab in Japan
Hideto Kameda¹, Toshiya Takahashi², Naoki Soeda² and Yoshiya Tanaka³, ¹Department of Internal Medicine, Toho University, Tokyo, Japan, ²Medical Affairs, Asahi Kasei Pharma Corporation, Tokyo, Japan, ³University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
Background/Purpose: The efficacy and safety of sarilumab (SAR) and methotrexate (MTX) in patients (pts) in Japan with moderate-to-severely active rheumatoid arthritis (RA) and inadequate response…
Abstract Number: 0471 • ACR Convergence 2025
An Open-label, Randomized, Controlled Phase 1/2 Study to Assess the Safety and Efficacy of KYV-101 Anti-CD19 CAR-T Cell Therapy in Active and Difficult-to-treat ACPA positive Rheumatoid Arthritis: Preliminary Results of the COMPARE Trial
Fredrik Albach¹, Ioanna Minopoulou¹, Artur Wilhelm², Robert Biesen¹, Arnd Kleyer¹, Norman Drzeniek³, Edgar Wiebe⁴, Anja Fleischmann³, Dominic Borie⁵, Vincent Casteleyn³, Tobias Alexander³, Christian Furth⁶, Jan Zernicke³, Burkhard Muche⁷, Sandra Hermann⁴, Pfeil Alexander⁸, Veronika Scholz³, Elpida Phithak³, Olaf Penack⁹, Kamran Movassaghi⁹, Eva Vanessa Schrezenmeier¹⁰, Udo Schneider³, Antonia Busse¹¹, Georg Schett¹², Ulrich Keller¹¹, Lars Bullinger⁹, Gerhard Krönke¹³, Marie Luise Hütter-Krönke¹⁴ and David Simon¹⁵, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Germany, ²Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, ³Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, ⁴Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Berlin, Germany, ⁵Kyverna Therapeutics, Emeryville, CA, ⁶Department of Nuclear Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany, Berlin, ⁷Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁸Department of Internal Medicine III, Jena University Hospital - Friedrich Schiller University Jena, Jena, Germany, ⁹Department of Hematology, Oncology and Tumor Immunology, Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany, Berlin, ¹⁰Department of Nephrology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, ¹¹Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, Campus Steglitz, Berlin, Germany; Max-Delbrück-Center for Molecular Medicine, Berlin, Germany; German Cancer Consortium (DKTK) partner site Charité Berlin and German Cancer Research Center (DKFZ), Heidelberg, Germany, Berlin, ¹²Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ¹³Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Berlin, Germany, ¹⁴Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, Campus Steglitz, Berlin, Germany, Berlin, ¹⁵Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Germany
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic autoimmune disease characterized by autoreactive B cells that produce anti-citrullinated protein antibodies (ACPA), contributing to sustained synovial inflammation…
Abstract Number: 0454 • ACR Convergence 2025
Models to predict flare and sustained remission in Rheumatoid Arthritis patients on optimization treatment with bDMARDs: clinical and molecular insights
Laura Galindo Domínguez¹, Belen Acasuso¹, Vanesa Balboa², Juan Cañete³, Benjamin Fernández-Gutiérrez⁴, Isidoro Gonzalez-Alvaro⁵, jose Luis Pablos⁶, Carmen Bejerano-Herreria⁷, Maite silva⁸, Ignacio rego Pérez⁹, Cristina Ruiz-Romero¹⁰, Francisco J De-Toro-Santos¹¹, Natividad Oreiro¹² and francisco J Blanco¹³, ¹Grupo de Investigación en Reumatología (GIR). INIBIC-Complejo Hospitalario Universitario A Coruña (CHUAC). SERGAS, A Coruña, Galicia, Spain, ²Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, coruña, Spain, ³Rheumatology Department, Hospital Clínic and IDIBAPS, Barcelona, Spain, Barcelona, Spain, ⁴Department of Rheumatology and Health Research Institute (IdISSC), Hospital Clínico San Carlos, Madrid, Spain., Madrid, Madrid, Spain, ⁵Department of Rheumatology, Hospital Universitario La Princesa, IIS, Madrid Spain, Madrid, Spain, ⁶Department of Rheumatology, Instituto de Investigación Hospital ¹² de Octubre, Complutense University of Madrid, Madrid, Madrid, Spain, ⁷Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ⁸Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, A Coruña, Spain, A Coruña, Galicia, Spain, ⁹Department of Rheumatology, Rheumatology Research Group (GIR) Biomedical Re-search Institute (INIBIC), A Coruña, Spain, ¹⁰Department of Rheumatology, Rheumatology Research Group (GIR) Biomedical Re-search Institute (INIBIC),, A Coruña, Spain, ¹¹Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, A Coruña, Spain, A Coruña, ¹²CHUAC, La Coruna, Spain, ¹³INIBIC-University of A Coruña, A Coruña, Galicia, Spain
Background/Purpose: Optimization of biologic DMARDs (bDMARDs) in patients with rheumatoid arthritis (RA) may be feasible in those who have maintained remission for at least six…
Abstract Number: 0437 • ACR Convergence 2025
Lipid Screening in Rheumatoid Arthritis: A Retrospective Cohort Study Highlighting Gaps in Cardiovascular Risk Prevention
Anokhi Saklecha¹, Amelia Khoo², Sierra Mendelsohn², Abhijeet Danve³, Mei Xue Dong⁴ and Lisa Suter², ¹Yale University, New Haven, CT, ²Yale School of Medicine, New Haven, CT, ³Section of Rheumatology, Department of Medicine, Yale School of Medicine, New Haven, CT, ⁴Yale-New Haven Medical Center, new haven, CT
Background/Purpose: Rheumatoid arthritis (RA) is associated with a 1.5 to 2 fold increased risk of cardiovascular disease (CVD) due to systemic inflammation and endothelial dysfunction.…
Abstract Number: 0343 • ACR Convergence 2025
Impact of Janus Kinase Inhibitors on Bone Mineral Density and Microarchitecture in Rheumatoid and Psoriatic Arthritis: Insights from a Real-World Cohort
Edgar Wiebe¹, Dörte Huscher², Zhivana Boyadzhieva³, Andriko Palmowski⁴, Sandra Hermann¹, Burkhard Muche⁴, Arnd Kleyer⁵, David Simon⁶, Gerhard Krönke⁷, Paula Hoff⁸ and FRANK BUTTGEREIT⁹, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Berlin, Germany, ²Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Berlin, Germany, ³Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Berlin, Germany, ⁴Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁵Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Germany, ⁶Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Germany, ⁷Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Berlin, Germany, ⁸Endokrinologikum Berlin, Medizinisches Versorgungszentrum (MVZ) am Gendarmenmarkt, Berlin, Berlin, Germany, ⁹Charité University Medicine Berlin, Berlin, Berlin, Germany
Background/Purpose: Janus kinase (JAK) inhibitors are an important treatment option for rheumatoid arthritis (RA) and psoriatic arthritis (PsA). By disrupting pro-inflammatory cytokine signaling (e.g., IL-6,…
Abstract Number: 0176 • ACR Convergence 2025
Development and Validation of an Accurate Patient Reported Outcome Measure-based Disease Activity Score to Enable Remote Monitoring in RA
Agnes Looijen¹, Paco Welsing², Sytske Anne Bergstra³, Annette van der Helm-van Mil³ and Pascal de Jong⁴, ¹Erasmus MC, Rotterdam, Netherlands, ²Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands, Utrecht, Netherlands, ³LUMC, Leiden, Netherlands, ⁴Erasmus University Medical Center, Rotterdam, the Netherlands, Rotterdam, Netherlands
Background/Purpose: For RA patients, regular monitoring of disease activity is essential, but in-person assessments may not always be feasible due to the increasing pressure on…
Abstract Number: 0093 • ACR Convergence 2025
Soluble CD13 engages protease-activated receptor 4 to promote synovial inflammation and angiogenesis in rheumatoid arthritis
Chenyang Lu¹, Megan N Mattichak², Simin Xu¹, William D Brodie³, Neha Khanna², Hafsa Amin², Qi Wu², Phillip Campbell², David Fox⁴ and Pei-Suen Tsou⁵, ¹Division of Rheumatology, Department of Internal Medicine, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, Guangzhou, China (People's Republic), ²Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA, Ann Arbor, ³Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, Ann Arbor, ⁴University of Michigan, Dexter, MI, ⁵University of Michigan, Ann Arbor, MI
Background/Purpose: Soluble CD13 (sCD13), the soluble form of aminopeptidase N/CD13, exhibits potent chemoattractant, angiogenic, and arthritogenic properties. While we previously identified certain G protein-coupled receptors…
Abstract Number: 0073 • ACR Convergence 2025
HLA-DQA1*01:02 Is Associated With IgG Multi-Reactivity With Citrulline-Containing Type II Collagen Epitopes While HLA-DRB*04:01 Is Associated With More Private Reactivity With Citrulline-Containing IgG Epitopes In Rheumatoid Arthritis
S. Janna Bashar¹, Courtney Myhr¹, Adam Titi¹, Zihao Zheng¹ and Miriam Shelef², ¹University of Wisconsin-Madison, Madison, ²University of Wisconsin-Madison, Madison, WI
Background/Purpose: Anti-citrullinated protein antibodies (ACPAs) in rheumatoid arthritis (RA) can be promiscuous, with cross-reactive binding to many antigens containing short motifs, or more private with…
Abstract Number: 0050 • ACR Convergence 2025
TL1A expression is upregulated in rheumatic diseases and anti-TL1A antibody reduces disease symptoms and pathological changes in rat collagen-induced arthritis
Preeyam Patel¹, Matthew Siegel², Emily Lewis³, David Giles³, Justin LaFountaine³, Joshua Friedman³ and Andy Spencer³, ¹Spyre Therapeutics, Waltham, ²Spyre Therapeutics, Menlo Park, CA, ³Spyre Therapeutics, Waltham, MA
Background/Purpose: The development of disease-modifying anti-rheumatic drugs (DMARDs) has reduced disease activity in patients living with rheumatic diseases. Despite this, there is continued unmet need…
Abstract Number: 2662 • ACR Convergence 2025
Target trial emulation of biologic and targeted synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis-associated interstitial lung disease
Gregory McDermott¹, Daniel Solomon², Jeffrey Sparks³ and Rishi Desai³, ¹Brigham and Women's Hospital, Brookline, MA, ²Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, MA
Background/Purpose: RA-ILD is associated with high mortality, but the optimal treatment approach is unclear. While immunosuppressants may treat inflammatory components of ILD, there are concerns…

Abstracts tagged "rheumatoid arthritis"

Safety Profile of ICIs in Patients with Rheumatoid Arthritis: Results from a Propensity Score-Matched Cohort Study

Association between inflammatory biomarkers and predicted heart failure risk in rheumatoid arthritis

Synovial Tissue Neutrophils are Associated with Disease Activity and Early Remission in Rheumatoid Arthritis

Altered expression of CD11c and HLA-DR on monocyte subsets in individuals at risk of rheumatoid and psoriatic arthritis

Spatial profiling of gene signatures in synovial tissue informs treatment strategy for Rheumatoid Arthritis

Efficacy of sarilumab in patients with rheumatoid arthritis of different disease activity at treatment initiation: a post-hoc analysis of a Phase 3 trial of sarilumab in Japan

An Open-label, Randomized, Controlled Phase 1/2 Study to Assess the Safety and Efficacy of KYV-101 Anti-CD19 CAR-T Cell Therapy in Active and Difficult-to-treat ACPA positive Rheumatoid Arthritis: Preliminary Results of the COMPARE Trial

Models to predict flare and sustained remission in Rheumatoid Arthritis patients on optimization treatment with bDMARDs: clinical and molecular insights

Lipid Screening in Rheumatoid Arthritis: A Retrospective Cohort Study Highlighting Gaps in Cardiovascular Risk Prevention

Impact of Janus Kinase Inhibitors on Bone Mineral Density and Microarchitecture in Rheumatoid and Psoriatic Arthritis: Insights from a Real-World Cohort

Development and Validation of an Accurate Patient Reported Outcome Measure-based Disease Activity Score to Enable Remote Monitoring in RA

Soluble CD13 engages protease-activated receptor 4 to promote synovial inflammation and angiogenesis in rheumatoid arthritis

HLA-DQA101:02 Is Associated With IgG Multi-Reactivity With Citrulline-Containing Type II Collagen Epitopes While HLA-DRB04:01 Is Associated With More Private Reactivity With Citrulline-Containing IgG Epitopes In Rheumatoid Arthritis

TL1A expression is upregulated in rheumatic diseases and anti-TL1A antibody reduces disease symptoms and pathological changes in rat collagen-induced arthritis

Target trial emulation of biologic and targeted synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis-associated interstitial lung disease